Enzytech (acq. by Alkermes)

Investment Year: 1986
Exit: 1993
Sector: Healthcare
Geography: North America - East

Developed mechanisms to deliver smaller doses of drugs specifically to their targets.

Team

Christopher Gabrieli

spotlight

Ethan Kurzweil Live in the TechStars Studio

BVP's Ethan Kurzweil, live in the TechStars studio, discuss SendGrid, Twilio and the new breed of API driven web infrastructure companies. The discussion is followed by a breakdown of the SendGrid pitch.

See the Video

Lifelock: Todd Davis

CEO Todd Davis talks about the Lifelock product and the keys to continued healthy growth

See the Video

Yelp: Jeremy Stoppelman

CEO Jeremy Stoppelman talks about what sets Yelp apart and his experience working with Bessemer

See the Video

Intucell: Rani Wellingstein

CEO Rani Wellington discusses Intucell's dynamic and automatic mobile network management platform, and the challenges of scaling a fast-growing company

See the Video

Mindbody: Rick Stollmeyer

CEO Rick Stollmeyer discusses the challenge of selling Saas software to the health and welfare industry

See the Video

Reputation.com: Michael Fertik

CEO Michael Fertik talks about Reputation.com's mission to give users control of their online reputations

See the Video

Twilio: Jeff Lawson

CEO Jeff Lawson talks about Twilio's simple web service API that allows developers to build live telephony applications in minutes

See the Video

Verastem: Christoph Westphal

CEO Christoph Westphal discusses how Verastem's focus on developing novel drugs targeting cancer stem cells could have a meaningful impact on cancer survival

See the Video

Bessemer Venture Partners